1,125 assets in Non-Small Cell Lung Carcinoma

Therapeutic assets addressing Non-Small Cell Lung Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
xb010 Non-Small Cell Lung Carcinoma	Exelixis	P1	CC (41)
yl201 Non-Small Cell Lung Carcinoma	MediLink Therapeutics (Suzhou) Co., Ltd.	P1/2	CC (41)
Zovostotug Non-Small Cell Lung Carcinoma	OncoResponse, Inc.	P1/2	CC (41)
1H-ISOINDOL-1-ONE, 7-((6-((DIMETHYLAMINO)METHYL)-5-((3S)-TETRAHYDRO-3-FURANYL)-2-PYRIDINYL)AMINO)-4-(7-FLUOROIMIDAZO(1,2-A)PYRIDIN-3-YL)-2,3-DIHYDRO- Non-Small Cell Lung Carcinoma	Nimbus Saturn, Inc.	P1/2	CC (40)
Afnt-211 Non-Small Cell Lung Carcinoma	Affini-T Therapeutics, Inc.	P1/2	CC (40)
Aguix Non-Small Cell Lung Carcinoma	Dana-Farber Cancer Institute	P1/2	CC (40)
ak138d1 Non-Small Cell Lung Carcinoma	Akeso	P1/2	CC (40)
Amt-116 Car-T Cells Non-Small Cell Lung Carcinoma	Beijing Immunochina Medical Science & Technology Co., Ltd.	P1/2	CC (40)
Amt-253 Car-T Cells Non-Small Cell Lung Carcinoma	Beijing Immunochina Medical Science & Technology Co., Ltd.	P1/2	CC (40)
ans014004 Non-Small Cell Lung Carcinoma	Beijing Pearl Biotechnology Limited Liability Company	P1/2	CC (40)
ans02 Non-Small Cell Lung Carcinoma	Avistone Biotechnology Co., Ltd.	P1/2	CC (40)
azd6750 Non-Small Cell Lung Carcinoma	AstraZeneca	P1/2	CC (40)
Benzoic Acid, 4-((4-Amino-3-(4-Cyclohexyl-1-Piperazinyl)-9,10-Dihydro-9,10-Dioxo-1-Anthracenyl)Amino)- Non-Small Cell Lung Carcinoma	VM Oncology, LLC	P1/2	CC (40)
Bl-M02D1 Non-Small Cell Lung Carcinoma	Sichuan Baili Pharmaceutical Co., Ltd.	P1/2	CC (40)
Blu-924 Non-Small Cell Lung Carcinoma	Blueprint Medicines Corporation	P1/2	CC (40)
Bms-986442 Non-Small Cell Lung Carcinoma	Bristol-Myers Squibb	P1/2	CC (40)
bnt326 Non-Small Cell Lung Carcinoma	BioNTech SE	P1/2	CC (40)
bnt327 Non-Small Cell Lung Carcinoma	BioNTech SE	P1/2	CC (40)
Bpi-361175 Non-Small Cell Lung Carcinoma	Xcovery Holdings, Inc.	P1/2	CC (40)
br790 Non-Small Cell Lung Carcinoma	Shanghai Gopherwood Biotech Co., Ltd.	P1/2	CC (40)
Camizestrant Non-Small Cell Lung Carcinoma	AstraZeneca	P1/2	CC (40)
cft1946 Non-Small Cell Lung Carcinoma	C4 Therapeutics, Inc.	P1	CC (40)
Ckd-703 Non-Small Cell Lung Carcinoma	Chong Kun Dang Pharmaceutical	P1/2	CC (40)
cp-383 Non-Small Cell Lung Carcinoma	Tasca Therapeutics	P1/2	CC (40)
cts2190 capsules Non-Small Cell Lung Carcinoma	CytosinLab Therapeutics Co., Ltd.	P1/2	CC (40)
Dazostinag Non-Small Cell Lung Carcinoma	Takeda	P1	CC (40)
Dositinib Mesylate Tablets Non-Small Cell Lung Carcinoma	Henan Genuine Biotech Co., Ltd.	P1/2	CC (40)
dsp107 Non-Small Cell Lung Carcinoma	Kahr Medical	P1/2	CC (40)
Dual-Target Car-Nk Cells Non-Small Cell Lung Carcinoma	Beijing Biotech	P1/2	CC (40)
Dupilumab Non-Small Cell Lung Carcinoma	Centre hospitalier de l'Université de Montréal (CHUM)	P1/2	CC (40)
Efavirenz Non-Small Cell Lung Carcinoma	Shenzhen TargetRx Co., Ltd.	P1	CC (40)
exl01 Non-Small Cell Lung Carcinoma	University Hospital, Lille	P1/2	CC (40)
Gecacitinib Non-Small Cell Lung Carcinoma	Suzhou Zelgen Biopharmaceuticals Co.,Ltd	P1/2	CC (40)
gen1107 Non-Small Cell Lung Carcinoma	Genmab	P1/2	CC (40)
Gen-725 Tablets Non-Small Cell Lung Carcinoma	Henan Genuine Biotech Co., Ltd.	P1/2	CC (40)
h002 Non-Small Cell Lung Carcinoma	RedCloud Bio	P1/2	CC (40)
h1299 cell lysates Non-Small Cell Lung Carcinoma	National Cancer Institute (NCI)	P1/2	CC (40)
her2bbζ/cd19t+ t cells Non-Small Cell Lung Carcinoma	Shanghai Public Health Clinical Center	P1/2	CC (40)
hlx301 Non-Small Cell Lung Carcinoma	Shanghai Henlius Biotech	P1/2	CC (40)
ibi318 Non-Small Cell Lung Carcinoma	Hunan Province Tumor Hospital	P2	CC (40)
imm60 Non-Small Cell Lung Carcinoma	iOx Therapeutics	P1/2	CC (40)
Immunoglobulin G1-Kappa, Anti-[Homo Sapiens Il2 (Interleukin 2)], Homo Sapiens Antibody; Gamma1 Heavy Chain Homo Sapiens (1-451) [Vh (Homo Sapiens Ighv1-2401 (84.5%) -(Ighd) -Ighj401 (92.9%), Cdr-Imgt [8.8.14] (26-33.51-58.97-110)) (1-121) -Homo Sapiens Ighg101, G1M17,1, G1V43 Ch2 A1.3, E1.2, A1 (Ch1 K120 (218) (122-219), Hinge 1-15 (220- 234), Ch2 L1.3>A (238), L1.2>E (239), (235- 344), Ch3 (345-449), Chs (450-451)) (122-451)], (224-220')-Disulfide With Kappa Light Chain Homo Sapiens (1'-220') [V-Kappa (Homo Sapiens Igkv4-101 (88.1%) -Igkj401 (90.9%), Cdr-Imgt [12.3.9] (27-38.56-58.95-103)) (1'-113') -Homo Sapiens Igkc01 (100%), Km3, A45.1 (159), V101 (197) (114'- 220')]; Dimer(230-230'':233-233'')-Bisdisulfide, Produced In Chinese Hamster Ovary (Cho) Cells, Derived From The Cell Line Cho-K1, Glycoform Alfa Non-Small Cell Lung Carcinoma	Aulos Bioscience, Inc.	P1/2	CC (40)
Inbrx-106 Non-Small Cell Lung Carcinoma	Inhibrx Biosciences, Inc	P1/2	CC (40)
Jab 21822 Non-Small Cell Lung Carcinoma	Allist Pharmaceuticals, Inc.	P1/2	CC (40)
jk08 Non-Small Cell Lung Carcinoma	Salubris Biotherapeutics Inc	P1/2	CC (40)
mdx2001 Non-Small Cell Lung Carcinoma	ModeX Therapeutics, An OPKO Health Company	P1/2	CC (40)
Naporafenib Non-Small Cell Lung Carcinoma	Novartis Pharmaceuticals	P1	CC (40)
Navlimetostat Non-Small Cell Lung Carcinoma	M.D. Anderson Cancer Center	P1/2	CC (40)
neo212 Non-Small Cell Lung Carcinoma	Neonc Technologies, Inc.	P1/2	CC (40)
Neoantigen Specific Tcr-T Cell Drug Product Non-Small Cell Lung Carcinoma	Alaunos Therapeutics	P1/2	CC (40)

Showing 751 to 800 of 1,125 assets

PreviousPage 16 of 23Next